Ibrutinib is a first-generation Bruton tyrosine kinase (BTK) inhibitor that became standard of care for the treatment of many B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma [32, 33]. This evidence concerns the gene BTK and mantle cell lymphoma.